NCT01370343

Single Dose Study Of The Effect Of Cyclosporine On The Pharmacokinetics Of PF-04991532 In Health Volunteers

A Phase 1, Single-Dose, Open-Label, Crossover Study To Assess The Effect Of Cyclosporine On The Pharmacokinetics Of PF-04991532 In Healthy Adult Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The primary purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of a single dose of PF-04991532 in healthy adult subjects with and without co-administration of cyclosporine.

Conditions

• Healthy
• Drug Interaction

Interventions

Type	Name	Description
DRUG	PF-04991532 alone	a single dose of 150 mg PF-04991532, fasted
DRUG	PF-04991532 + cyclosporine	a single dose of 150 mg PF-04991532 + a single dose of 600 mg cyclosporine, fasted

Timeline

• Start date: 2011-07-01
• Primary completion: 2011-07-01
• Completion: 2011-07-01
• First posted: 2011-06-09
• Last updated: 2011-09-07

Locations

1 site across 1 country: Belgium